Saxo-Market-Call_Platform_1920x1280_Test 5

Countdown to Mar-a-Lago Accord just begun?

Podcast 28 minutes to read
Saxo Logo
Saxo Market Call

Summary:  Today we cover the chaos in the gold market on the US moving to tariff certain classes of bullion, Trump's executive order to allow bitcoin and cryptocurrency holdings in 401k accounts, geopolitics and crude, and most importantly, the possibly massive implications of Trump's nomination of Stephen Miran to occupy the empty seat on the Fed Board. Today's pod features Saxo Head of Commodity Strategy Ole Hansen and Saxo Global Head of Macro Strategy John J. Hardy.



Listen to the full episode now or follow the Saxo Market Call on your favorite podcast app.

Today's slide deck for the podcast.

Today’s links

My FX Update from today, wondering if both CHF and GBP can fall, if for very different reasons - sterling for structural reasons, and the Swiss franc as it is singled out by the Trump administration.

With Trump’s appointment of Stephen Miran to the Fed, time to re-read the original piece he wrote that went viral across hedge funds and among the commentariat: A User’s Guide to Restructuring the Global Trading System, reminding everyone the scale of what could be under way, who knows even something resembling a “Mar a Lago Accord”. Is Miran’s appointment to the Fed a step in the direction of getting the US Treasury and Fed on the same page to mobilize a massive initiative to further upend the global trading system and the US dollar’s place in it, now that the tariffs are largely in place?

A reminder for those who aren’t to follow Michael Every’s daily geopolitical updates on X, like the excellent one from today.

ChatGPT 5.0 is out and this is a major upgrade with considerable new possibilities - the OpenAI team runs you through what you can do with it.

For those wondering whether the US economy risks a recession, worth having a look here and considering that for many Americans, it is already in a depression.

 

Chart of the Day - Novo Nordisk

A bit of relief for the beleaguered Novo stock yesterday, as Eli Lilly’s announced that its pill-form obesity drug didn’t perform as well as some hoped in trials. The pill-game for obesity treatment seems to be the next one for both companies, and Novo claims that its pill may be the best in class once released next year. Its stock has cratered as the market reassessed its competitiveness in the market for injectable obesity treatments and potential growth path. While the stock is up well over 10% from the lows this week, it is useful to zoom out to a weekly chart and, oh my goodness, there is a lot of damage done from the highs above DKK 1,000 per share. To even get started on any climb back higher, the stock needs to quickly erase that massive sell-off bar last week from 464 to 308. At 325 currently, some very heavy lifting indeed required.

08_08_2025_Novo
Source: Saxo

Questions and comments, please!

We invite you to send any questions and comments you might have for the podcast team. Whether feedback on the show's content, questions about specific topics, or requests for more focus on a given market area in an upcoming podcast, please get in touch at marketcall@saxobank.com.

This content is marketing material and should not be considered investment advice. Trading financial instruments carries risks and historic performance is not a guarantee for future performance.

The instrument(s) mentioned in this content may be issued by a partner, from which Saxo receives promotion, payment or retrocessions. While Saxo receives compensation from these partnerships, all content is conducted with the intention of providing clients with valuable options and information.

Quarterly Outlook

01 /

  • Q3 Investor Outlook: Beyond American shores – why diversification is your strongest ally

    Quarterly Outlook

    Q3 Investor Outlook: Beyond American shores – why diversification is your strongest ally

    Jacob Falkencrone

    Global Head of Investment Strategy

  • Q3 Macro Outlook: Less chaos, and hopefully a bit more clarity

    Quarterly Outlook

    Q3 Macro Outlook: Less chaos, and hopefully a bit more clarity

    John J. Hardy

    Global Head of Macro Strategy

    After the chaos of Q2, the quarter ahead should get a bit more clarity on how Trump 2.0 is impacting...
  • Equity outlook: The high cost of global fragmentation for US portfolios

    Quarterly Outlook

    Equity outlook: The high cost of global fragmentation for US portfolios

    Charu Chanana

    Chief Investment Strategist

  • Commodity Outlook: Commodities rally despite global uncertainty

    Quarterly Outlook

    Commodity Outlook: Commodities rally despite global uncertainty

    Ole Hansen

    Head of Commodity Strategy

  • Upending the global order at blinding speed

    Quarterly Outlook

    Upending the global order at blinding speed

    John J. Hardy

    Global Head of Macro Strategy

    We are witnessing a once-in-a-lifetime shredding of the global order. As the new order takes shape, ...
  • Asset allocation outlook: From Magnificent 7 to Magnificent 2,645—diversification matters, now more than ever

    Quarterly Outlook

    Asset allocation outlook: From Magnificent 7 to Magnificent 2,645—diversification matters, now more than ever

    Jacob Falkencrone

    Global Head of Investment Strategy

  • Macro outlook: Trump 2.0: Can the US have its cake and eat it, too?

    Quarterly Outlook

    Macro outlook: Trump 2.0: Can the US have its cake and eat it, too?

    John J. Hardy

    Global Head of Macro Strategy

  • Equity Outlook: The ride just got rougher

    Quarterly Outlook

    Equity Outlook: The ride just got rougher

    Charu Chanana

    Chief Investment Strategist

  • China Outlook: The choice between retaliation or de-escalation

    Quarterly Outlook

    China Outlook: The choice between retaliation or de-escalation

    Charu Chanana

    Chief Investment Strategist

  • Commodity Outlook: A bumpy road ahead calls for diversification

    Quarterly Outlook

    Commodity Outlook: A bumpy road ahead calls for diversification

    Ole Hansen

    Head of Commodity Strategy

None of the information provided on this website constitutes an offer, solicitation, or endorsement to buy or sell any financial instrument, nor is it financial, investment, or trading advice. Saxo Capital Markets UK Ltd. (Saxo) and the Saxo Bank Group provides execution-only services, with all trades and investments based on self-directed decisions. Analysis, research, and educational content is for informational purposes only and should not be considered advice nor a recommendation. Access and use of this website is subject to: (i) the Terms of Use; (ii) the full Disclaimer; (iii) the Risk Warning; and (iv) any other notice or terms applying to Saxo’s news and research.

Saxo’s content may reflect the personal views of the author, which are subject to change without notice. Mentions of specific financial products are for illustrative purposes only and may serve to clarify financial literacy topics. Content classified as investment research is marketing material and does not meet legal requirements for independent research.

Before making any investment decisions, you should assess your own financial situation, needs, and objectives, and consider seeking independent professional advice. Saxo does not guarantee the accuracy or completeness of any information provided and assumes no liability for any errors, omissions, losses, or damages resulting from the use of this information.

Please refer to our full disclaimer for more details. Past Performance is not indicative of future results.

Saxo
40 Bank Street, 26th floor
E14 5DA
London
United Kingdom

Contact Saxo

Select region

United Kingdom
United Kingdom

Trade Responsibly
All trading carries risk. To help you understand the risks involved we have put together a series of Key Information Documents (KIDs) highlighting the risks and rewards related to each product. Read more
Additional Key Information Documents are available in our trading platform.

Saxo is a registered Trading Name of Saxo Capital Markets UK Ltd (‘Saxo’). Saxo is authorised and regulated by the Financial Conduct Authority, Firm Reference Number 551422. Registered address: 26th Floor, 40 Bank Street, Canary Wharf, London E14 5DA. Company number 7413871. Registered in England & Wales.

This website, including the information and materials contained in it, are not directed at, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in the United States, Belgium or any other jurisdiction where such distribution, publication, availability or use would be contrary to applicable law or regulation.

It is important that you understand that with investments, your capital is at risk. Past performance is not a guide to future performance. It is your responsibility to ensure that you make an informed decision about whether or not to invest with us. If you are still unsure if investing is right for you, please seek independent advice. Saxo assumes no liability for any loss sustained from trading in accordance with a recommendation.

Apple, iPad and iPhone are trademarks of Apple Inc., registered in the U.S. and other countries. App Store is a service mark of Apple Inc. Android is a trademark of Google Inc.

©   since 1992